Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Skin Cancer01:30

Skin Cancer

4.0K
Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
4.0K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

6.4K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K
Metastasis02:30

Metastasis

5.5K
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
5.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Bintrafusp alfa for patients with recurrent or metastatic olfactory neuroblastoma.

Cancer immunology, immunotherapy : CII·2026
Same author

Expansion of pathogens and restoration of human skin microbiome in CD4 T-cell lymphopenia.

The Journal of investigative dermatology·2026
Same author

Merkel cell carcinoma virus positivity ranges from 57% to 77% in the United States based on geographic region: A pooled cohort study.

Journal of the American Academy of Dermatology·2026
Same author

Acute T-cell leukemia/lymphoma presenting with leukemia cutis mimicking prurigo nodularis.

JAAD case reports·2026
Same author

Immunotherapy Significantly Improves Merkel Cell Carcinoma-Specific Survival: A Single-Cohort Propensity Score-Matched Analysis.

medRxiv : the preprint server for health sciences·2026
Same author

ATP13A2 Loss of Function-Driven Polyamine Dysregulation Induces SAM Depletion and Epigenetic Astrocyte Toxicity.

bioRxiv : the preprint server for biology·2026
Same journal

Palliative Therapy for Liver and Biliary Neoplasms.

Hematology/oncology clinics of North America·2026
Same journal

Ablative Therapies for Liver Tumors.

Hematology/oncology clinics of North America·2026
Same journal

Pathology of Liver and Biliary Neoplasms.

Hematology/oncology clinics of North America·2026
Same journal

Minimally Invasive Surgery for Liver and Biliary Tract Neoplasms.

Hematology/oncology clinics of North America·2026
Same journal

Surgical Considerations for Primary Liver Neoplasms.

Hematology/oncology clinics of North America·2026
Same journal

Systemic Therapy for Biliary and Liver Neoplasms: Chemotherapy and Immunotherapy.

Hematology/oncology clinics of North America·2026
See all related articles

Related Experiment Video

Updated: Jun 19, 2025

Merkel Cell Polyomavirus Infection and Detection
13:45

Merkel Cell Polyomavirus Infection and Detection

Published on: February 7, 2019

9.9K

Merkel Cell Carcinoma.

Jennifer Strong1, Patrick Hallaert1, Isaac Brownell1

  • 1Dermatology Branch, NIAMS, NIH, 10 Center Drive, 12N240C, Bethesda, MD 20892-1908, USA.

Hematology/Oncology Clinics of North America
|July 26, 2024
PubMed
Summary
This summary is machine-generated.

Merkel cell carcinoma (MCC), a rare skin cancer, is effectively treated with immunotherapy. Research is ongoing to optimize treatment duration and explore alternatives for refractory cases.

Keywords:
ImmunotherapyMerkel cell carcinomaMerkel cell polyomavirusNeuroendocrineSkin cancer

More Related Videos

Patient Derived Cell Culture and Isolation of CD133+ Putative Cancer Stem Cells from Melanoma
12:16

Patient Derived Cell Culture and Isolation of CD133+ Putative Cancer Stem Cells from Melanoma

Published on: March 13, 2013

21.3K
Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells
06:09

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells

Published on: June 7, 2019

8.7K

Related Experiment Videos

Last Updated: Jun 19, 2025

Merkel Cell Polyomavirus Infection and Detection
13:45

Merkel Cell Polyomavirus Infection and Detection

Published on: February 7, 2019

9.9K
Patient Derived Cell Culture and Isolation of CD133+ Putative Cancer Stem Cells from Melanoma
12:16

Patient Derived Cell Culture and Isolation of CD133+ Putative Cancer Stem Cells from Melanoma

Published on: March 13, 2013

21.3K
Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells
06:09

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells

Published on: June 7, 2019

8.7K

Area of Science:

  • Oncology
  • Dermatology
  • Immunology

Background:

  • Merkel cell carcinoma (MCC) is a rare, aggressive neuroendocrine skin cancer.
  • MCC exhibits high radiosensitivity and immunogenicity.
  • Immunotherapy, particularly immune checkpoint inhibitors, is the primary treatment for advanced MCC.

Purpose of the Study:

  • To review the characteristics and management of Merkel cell carcinoma.
  • To highlight recent innovations and areas of active investigation in MCC treatment.
  • To discuss the role of immunotherapy and emerging biomarkers in MCC.

Main Methods:

  • This is a review article, synthesizing existing research and clinical findings.
  • The review covers epidemiology, pathology, diagnosis, and treatment modalities for MCC.
  • Focus is placed on immunotherapy, neoadjuvant/adjuvant therapy, and biomarker research.

Main Results:

  • Immune checkpoint inhibitors show promise in neoadjuvant or adjuvant settings for high-risk MCC.
  • Emerging biomarkers for tumor burden are crucial for risk stratification and surveillance.
  • Optimal duration of anti-PD-(L)1 therapy and second-line options for refractory MCC require further investigation.

Conclusions:

  • Immunotherapy is a cornerstone in advanced Merkel cell carcinoma management.
  • Biomarker research and further clinical trials are essential for refining MCC treatment strategies.
  • Continued research is needed to address treatment resistance and optimize long-term outcomes.